TheraRadar
← Back
Data updated: May 24, 2026

BLUEPRINT MEDICINES

Pharma
OncologyGastroenterologyMetabolic Execution: Fair

BLUEPRINT MEDICINES is a pharmaceutical company focused on Oncology, Gastroenterology, Metabolic. Key products include AYVAKIT.

2020
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules
Novel Drugs (2020):
2 Novel Approvals 2 Orphan Drug 2 Breakthrough

BLUEPRINT MEDICINES at a Glance

  • Leading 6 drug targets across portfolio
  • Fast trial execution (31 months median completion)

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

AYVAKIT
Oncology

Gastrointestinal Stromal Tumor

CSF1R Approved 2020
GAVRETO
Oncology

Metastatic RET fusion-positive non-small cell lung cancer

DDR1 Approved 2020

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Oncology 60%
2 drugs Phase 2: 1 Phase 1: 10
Gastroenterology 25%
1 drugs Phase 1: 4
Metabolic 15%
1 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

0
Phase 3
1
Phase 2
14
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • AYVAKIT leads revenue
  • • 2 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 1/1 completed
  • • Speed: 31 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges